The pharmaceutical company Farmausa Life Science has obtained registration for its Cannabidiol in two concentrations, 20 mg/mL and 100 mg/mL, with low THC content

Brazilian delegation led by Abiquifi participates in a mission to Colombia to exchange experiences on the regulation of cannabis cultivation, with representatives from MAPA, Anvisa, Embrapa, and major pharmaceutical industries

Anvisa has prohibited the manufacturing, sale, and promotion of CBD Brasil's cannabis products due to lack of sanitary authorization

Minister Regina Helena Costa states that this will be the last extension and orders Anvisa to report compliance with each intermediate step of the plan

Director-General of the National Narcotics Fund of Colombia, Milver Rojas, states that the process will be immediate once Anvisa confirms and foresees a return to the four to five-day deadline for each authorization

New authorization expands the university's scope in Reblas and reinforces the quality control of plant derivatives in the national market

According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and greater medical adherence

Expansion of the institute in the sector, however, depends on new authorizations from Anvisa for the quality control of plant-based raw materials

Company demands urgent measures in face of new missed deadlines by the government and Anvisa and proposes experimental environment under judicial supervision

The agency determined the suspension of the commercialization and advertising of all items from the brands Golden CBD Plus and Golden CBD+ Nanotech in the national territory.

Pharmaceutical company Ephar has obtained registration for its Cannabidiol in two concentrations, 50 mg/mL and 100 mg/mL, which will be marketed in a low THC content drop solution.

Regulatory agency bans commercialization and advertising of items from the brands due to lack of sanitary authorization; understand the decision and the companies' positions

Regulatory agency determines the seizure of all batches from the company and another distributor due to irregularities in registration and manufacturing

The use of medicinal cannabis in pets has been growing in Brazil since Anvisa's authorization in 2024, bringing relief for chronic pain, epilepsy, and anxiety in animals, and renewed hope for pet owners

Thiago Campos advocates for the extension of the regulation deadline and reinforces the importance of social listening in the process

Cannten's extract with 71.33 mg/mL expands medicinal treatment options in the country and receives authorization for commercialization

The subject is on the agenda of the 6th Public Meeting of the Collegiate Board of Directors (Dicol) of 2025, scheduled for Wednesday (10/08)

Extract from the company Endogen expands the portfolio of options for medicinal treatments and already has sanitary authorization for commercialization

Without defined rules, veterinarians face legal uncertainty and animals still have limited access to medicinal cannabis treatment

Ministry of Health and Anvisa claim technical complexity and propose a new schedule that extends until March 2026 to define the rules